Vimarsana
Biggest News Aggregation in the World

Page 49 - Immunic Inc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Immunic Inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Immunic Inc Today - Breaking & Trending Today

DGAP-News: Immunic, Inc. Announces Positive Top-Line Data From Investigator-Sponsored Phase 2 Proof-of-Concept Clinical Trial of IMU-838 in Primary Sclerosing Cholangitis - Vimarsana News

DGAP-News: Immunic, Inc. Announces Positive Top-Line Data From Investigator-Sponsored Phase 2 Proof-of-Concept Clinical Trial of IMU-838 in Primary Sclerosing Cholangitis

DGAP-News: Immun ... DGAP-News: Immunic, Inc. Announces Positive Top-Line Data From Investigator-Sponsored Phase 2 Proof-of-Concept Clinical Trial of IMU-838 in Primary Sclerosing Cholangitis vom 18.02.2021, 12:30 Uhr Bild: pixabay.com DGAP-News: Immunic, Inc. / Key word(s): Study results Immunic, Inc. Announces Positive Top-Line Data From Investigator-Sponsored Phase 2 Proof-of-Concept Clinical Trial of IMU-838 in Primary Sclerosing Cholangitis 18.02.2021 / 12:30 The issuer is solely responsible for the content of this announcement. Immunic, Inc. Announces Positive Top-Line Data F...

Liver Disease - Vimarsana News

Liver Disease

Markets were relatively calm during Thursday's trading session as investors anticipate Friday's jobs report. The December employment report is expected to show about 200,000 payroll jobs representing a steady growth and a clear sign that labor market and economy are both strong. Related:... Read More... Don't Miss Any Updates! News Directly in Your Inbox Subscribe to:

Immunic, Inc. Announces That Oral Treatment IMU-838 Shows Evidence of Clinical Activity in Moderate COVID-19 in Phase 2 CALVID-1 Trial - Vimarsana News

Immunic, Inc. Announces That Oral Treatment IMU-838 Shows Evidence of Clinical Activity in Moderate COVID-19 in Phase 2 CALVID-1 Trial

/PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at...

(IMUX) - IMU-838 Data In COVID-19 Study Fails To Cheer Immunic Investors; Stock Tanks - Vimarsana News

(IMUX) - IMU-838 Data In COVID-19 Study Fails To Cheer Immunic Investors; Stock Tanks

Immunic Inc (NASDAQ: IMUX) completes the main analysis of Phase 1 CALVID-1 trial evaluating its lead asset, IMU-838. It is a ...

Related Topics:
Immunic Inc
DGAP-News: Immunic, Inc. Announces That Oral Treatment IMU-838 Shows Evidence of Clinical Activity in Moderate COVID-19 in Phase 2 CALVID-1 Trial - Vimarsana News

DGAP-News: Immunic, Inc. Announces That Oral Treatment IMU-838 Shows Evidence of Clinical Activity in Moderate COVID-19 in Phase 2 CALVID-1 Trial

DGAP-News: Immunic, Inc. Announces That Oral Treatment IMU-838 Shows Evidence of Clinical Activity in Moderate COVID-19 in Phase 2 CALVID-1 Trial Table: IMU-838 Shows Acceleration of Time to Clinical Improvement High-risk patients and patients aged over 65 years experienced a more substantial treatment benefit from IMU-838 than in the general patient population: - The 75% probability [5] to reach clinical improvement (based on investigator assessment) was accelerated by 3.8 days in IMU-838 treated high-risk patients [6], as compared to placebo (FAS). - The 75% probability [5] to reach clinica...